To determine the genetic risk of susceptibility to, or severity of community-acquired pneumonia by comparing the interpersonal genetic variation of the host immune response of patients with community-acquired pneumonia to healthy controls and by…
ID
Source
Brief title
Condition
- Bacterial infectious disorders
- Respiratory tract infections
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
1.To identify genetics variations associated with the genetic risk of
susceptibility to community-acquired pneumonia.
Secondary outcome
1.To identify genetic variations associated with a severe community-acquired
pneumonia on admission. Pneumonia severity will be determined by (a) mortality
of community-acquired pneumonia within 24 hours; (b) Pneumonia severity scores:
Pneumonia Severity Index and CURB-65 score (appendix 4) and (c) Location of
treatment after first survey in ER (ward versus ICU).
2.To indentify genetic variations associated with poor response to treatment:
determined by (a) development of complications during hospitalization (b)
mortality after first day and within 30 days of admission. (c) admission to ICU
during hospitalization.
Background summary
Community-acquired Pneumonia is still the most important causes of hospital
admission and mortality due to infectious diseases in western countries.
Insight into the genetic variability in the host response to community-acquired
pneumonia seems promising and will lead to a better understanding of the
biological role of different genes and their products in the pathogenesis of
pneumonia. Moreover, a better insight into the influence of host genetic
variation on the pathophysiological derangements and severity of pulmonary
infections seems vital in order to develop new therapeutic approaches and more
individualized treatment for community-acquired pneumonia.
Study objective
To determine the genetic risk of susceptibility to, or severity of
community-acquired pneumonia by comparing the interpersonal genetic variation
of the host immune response of patients with community-acquired pneumonia to
healthy controls and by comparing interpersonal genetic variation of the host
response in patients with variable degree of pneumonia severity.
Study design
The study is designed as prospective multicenter case-control study; a
genome-wide association study. We intent to collect blood samples from 2000
patients with community-acquired pneumonia admitted to one of the participating
hospitals.
Genotyping will be used to identify subtle genetic variations, which may be
associated with and increased risk of susceptibility to/or severity of
community-acquired pneumonia. To identify these genetic variations genotype
results of 2000 patients with community-acquired pneumonia be related to 2000
population controls.
Study burden and risks
none
postbus 85500
3508 GA Utrecht
NL
postbus 85500
3508 GA Utrecht
NL
Listed location countries
Age
Inclusion criteria
1.Age of 18 years of older
2.Admission to the hospital
3.Community-acquired pneumonia defined as:
a.New or progressive infiltrate on a chest X-ray and
b.2 of the following criteria:
-Cough
-sputum production
-dyspnea
-rectal temperature > 38oC or < 36.1oC
-ausculatory findings consistent with pneumonia
-leucocytosis (>10.000/mm3, or >15% bands)
-C-reactive protein > 3 times the upper limit of normal
4. A least three grandparents form Dutch origin
Exclusion criteria
1.Hospitalization for more than >=48h in the 2 weeks prior to enrollment in the study
2.Infections other than pneumonia that need immediate treatment
3.Life expectancy < 2 months
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL25409.041.08 |